Tags

Type your tag names separated by a space and hit enter

Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.
Front Immunol. 2019; 10:2192.FI

Abstract

The Yellow Fever (YF) vaccination is recommended for people living in endemic areas and represents the most effective strategy to reduce the risk of infection. Previous studies have warned that booster regimens should be considered to guarantee the long-term persistence of 17DD-YF-specific memory components in adults living in areas with YF-virus circulation. Considering the lower seroconversion rates observed in children (9-12 months of age) as compared to adults, this study was designed in order to access the duration of immunity in single-dose vaccinated children in a 10-years cross-sectional time-span. The levels of neutralizing antibodies (PRNT) and the phenotypic/functional memory status of T and B-cells were measured at a baseline, 30-45 days, 1, 2, 4, 7, and 10 years following primary vaccination. The results revealed that a single dose induced 85% of seropositivity at 30-45 days and a progressive time-dependent decrease was observed as early as 2 years and declines toward critical values (below 60%) at time-spans of ≥4-years. Moreover, short-lived YF-specific cellular immunity, mediated by memory T and B-cells was also observed after 4-years. Predicted probability and resultant memory analysis emphasize that correlates of protection (PRNT; effector memory CD8+ T-cells; non-classical memory B-cells) wane to critical values within ≥4-years after primary vaccination. Together, these results clearly demonstrate the decline of 17DD-YF-specific memory response along time in children primarily vaccinated at 9-12 months of age and support the need of booster regimen to guarantee the long-term persistence of memory components for children living in areas with high risk of YF transmission.

Authors+Show Affiliations

Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, Brazil.Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, Brazil.Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, Brazil.Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, Brazil.Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, Brazil.Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, Brazil.Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, Brazil.Departamento de Fisiologia e Biofísica, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, Brazil.Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, Brazil.Secretaria Municipal de Saúde de Belo Horizonte, Belo Horizonte, Brazil.Secretaria do Estado de Saúde de Minas Gerais, Belo Horizonte, Brazil.Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, Brazil.Escola Nacional de Saúde Pública - FIOCRUZ, Rio de Janeiro, Brazil.Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos - FIOCRUZ, Rio de Janeiro, Brazil.Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos - FIOCRUZ, Rio de Janeiro, Brazil.Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos - FIOCRUZ, Rio de Janeiro, Brazil.Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos - FIOCRUZ, Rio de Janeiro, Brazil.Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos - FIOCRUZ, Rio de Janeiro, Brazil.Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos - FIOCRUZ, Rio de Janeiro, Brazil.Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos - FIOCRUZ, Rio de Janeiro, Brazil.Faculdade de Medicina, Universidade de Brasília, Brasilia, Brazil.Instituto Evandro Chagas, Ananindeua, Brazil.Departamento de Imunização e Doenças Transmissíveis (DEIDT) - Secretaria de Vigilância em Saúde, Ministério da Saúde, Brasilia, Brazil.Programa Nacional de Imunizações - Secretaria de Vigilância em Saúde, Ministério da Saúde, Brasilia, Brazil.Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, Brazil.Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, Brazil.

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

31616412

Citation

Campi-Azevedo, Ana Carolina, et al. "Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children." Frontiers in Immunology, vol. 10, 2019, p. 2192.
Campi-Azevedo AC, Reis LR, Peruhype-Magalhães V, et al. Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children. Front Immunol. 2019;10:2192.
Campi-Azevedo, A. C., Reis, L. R., Peruhype-Magalhães, V., Coelho-Dos-Reis, J. G., Antonelli, L. R., Fonseca, C. T., Costa-Pereira, C., Souza-Fagundes, E. M., da Costa-Rocha, I. A., Mambrini, J. V. M., Lemos, J. A. C., Ribeiro, J. G. L., Caldas, I. R., Camacho, L. A. B., Maia, M. L. S., de Noronha, T. G., de Lima, S. M. B., Simões, M., Freire, M. D. S., ... Martins-Filho, O. A. (2019). Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children. Frontiers in Immunology, 10, 2192. https://doi.org/10.3389/fimmu.2019.02192
Campi-Azevedo AC, et al. Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children. Front Immunol. 2019;10:2192. PubMed PMID: 31616412.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children. AU - Campi-Azevedo,Ana Carolina, AU - Reis,Laise Rodrigues, AU - Peruhype-Magalhães,Vanessa, AU - Coelho-Dos-Reis,Jordana Grazziela, AU - Antonelli,Lis Ribeiro, AU - Fonseca,Cristina Toscano, AU - Costa-Pereira,Christiane, AU - Souza-Fagundes,Elaine Maria, AU - da Costa-Rocha,Ismael Artur, AU - Mambrini,Juliana Vaz de Melo, AU - Lemos,Jandira Aparecida Campos, AU - Ribeiro,José Geraldo Leite, AU - Caldas,Iramaya Rodrigues, AU - Camacho,Luiz Antônio Bastos, AU - Maia,Maria de Lourdes de Sousa, AU - de Noronha,Tatiana Guimarães, AU - de Lima,Sheila Maria Barbosa, AU - Simões,Marisol, AU - Freire,Marcos da Silva, AU - Martins,Reinaldo de Menezes, AU - Homma,Akira, AU - Tauil,Pedro Luiz, AU - Vasconcelos,Pedro Fernando Costa, AU - Romano,Alessandro Pecego Martins, AU - Domingues,Carla Magda, AU - Teixeira-Carvalho,Andréa, AU - Martins-Filho,Olindo Assis, Y1 - 2019/09/26/ PY - 2019/06/26/received PY - 2019/08/30/accepted PY - 2019/10/17/entrez PY - 2019/10/17/pubmed PY - 2020/10/21/medline KW - 17DD vaccine KW - cellular memory KW - children KW - neutralizing antibodies KW - yellow fever SP - 2192 EP - 2192 JF - Frontiers in immunology JO - Front Immunol VL - 10 N2 - The Yellow Fever (YF) vaccination is recommended for people living in endemic areas and represents the most effective strategy to reduce the risk of infection. Previous studies have warned that booster regimens should be considered to guarantee the long-term persistence of 17DD-YF-specific memory components in adults living in areas with YF-virus circulation. Considering the lower seroconversion rates observed in children (9-12 months of age) as compared to adults, this study was designed in order to access the duration of immunity in single-dose vaccinated children in a 10-years cross-sectional time-span. The levels of neutralizing antibodies (PRNT) and the phenotypic/functional memory status of T and B-cells were measured at a baseline, 30-45 days, 1, 2, 4, 7, and 10 years following primary vaccination. The results revealed that a single dose induced 85% of seropositivity at 30-45 days and a progressive time-dependent decrease was observed as early as 2 years and declines toward critical values (below 60%) at time-spans of ≥4-years. Moreover, short-lived YF-specific cellular immunity, mediated by memory T and B-cells was also observed after 4-years. Predicted probability and resultant memory analysis emphasize that correlates of protection (PRNT; effector memory CD8+ T-cells; non-classical memory B-cells) wane to critical values within ≥4-years after primary vaccination. Together, these results clearly demonstrate the decline of 17DD-YF-specific memory response along time in children primarily vaccinated at 9-12 months of age and support the need of booster regimen to guarantee the long-term persistence of memory components for children living in areas with high risk of YF transmission. SN - 1664-3224 UR - https://www.unboundmedicine.com/medline/citation/31616412/Short_Lived_Immunity_After_17DD_Yellow_Fever_Single_Dose_Indicates_That_Booster_Vaccination_May_Be_Required_to_Guarantee_Protective_Immunity_in_Children_ L2 - https://doi.org/10.3389/fimmu.2019.02192 DB - PRIME DP - Unbound Medicine ER -